Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Characteristics and treatment regimens across ERS SHARP severe asthma registries

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. ERS/TSANZ Task Force Statement on the Management of Reproduction and Pregnancy in Women with Airways Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Latent tuberculosis infection among minor asylum seekers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Primary ciliary dyskinesia patients have the same P. aeruginosa clone in sinuses and lungs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. ERS and tobacco harm reduction

    Publikation: Bidrag til tidsskriftLederForskning

  • SHARP Clinical Research Collaboration
Vis graf over relationer

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

TidsskriftThe European Respiratory Journal
Udgave nummer1
StatusUdgivet - jan. 2020

Bibliografisk note

Copyright ©ERS 2020.

ID: 59244844